
|Articles|December 1, 2005
- Volume 0 0
FDA Reviews Trexima for Treatment of Migraines
Author(s)Susan Farley
Advertisement
GlaxoSmithKline and POZEN Inc announced that the drugTrexima will be reviewed by the FDA for the acute treatmentof migraine headaches. The companies have proposed Treximaas the brand name for their combination of sumatriptansuccinate (Imitrex) and naproxen sodium (Aleve, for example)in a single-tablet form. Pending approval by the FDA, Treximacould be available to the public by the second half of 2006.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Articles in this issue
over 20 years ago
CAN YOU READ THESE Rxs?over 20 years ago
Bar Coding Thwarts Illegitimate Drug Useover 20 years ago
Hypertension Counseling Requires a Multifactorial Approachover 20 years ago
COMPOUNDING HOTLINEover 20 years ago
Pharmacy Law: Duty to Warn Waived When Patient Refuses Counselingover 20 years ago
EnterpriseRx Pharmacy Management Systemover 20 years ago
Hospital Installs Automated Medication Cabinetsover 20 years ago
"Smartphones" Help with Clinical Trial Informationover 20 years ago
HIT Needs Medicare's LeadershipAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
First-Ever Guideline on Cardio-Kidney-Metabolic Syndrome Calls for Earlier Screening, Coordinated Care
2
Peptide Therapy for Weight Loss: Separating Clinical Promise From Social Media Hype
3
ADA 2026: Distinguishing T1D From T2D in Adults: What the Data Tell Us
4
ADA 2026: Subcutaneous Furosemide May Reduce Heart Failure Hospitalizations in Patients With Diabetes
5





































































































































